Recent Quotes
My Watchlist
Indicators
Local Stocks
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

41.34 +1.48 (+3.70%)
Streaming Delayed Price Updated: 12:24 PM EST, Feb 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Corcept Therapeutics Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
CORT Shares Plummet On FDA’s Drug Rejection Letter Reveal — Here’s What Retail Has To Say ↗
As per the letter published by the FDA, the agency had alerted the company regarding its concerns for Relacorilant before. 
Via Stocktwits
What's going on in today's after hours session ↗
Via Chartmill
News headline image
Corcept Therapeutics (CORT): A Deep Dive into the 43.7% Earnings Growth and the High-Stakes Pivot to Oncology
As of January 28, 2026, Corcept Therapeutics (NASDAQ: CORT) stands at a critical crossroads that perfectly encapsulates the high-stakes nature of the biotechnology sector. Once a niche player focused... 
Via Finterra
Topics Economy Intellectual Property
Corcept Therapeutics Inc (NASDAQ:CORT) Fits the Affordable Growth Profile ↗
Via Chartmill
Why Is CORT Stock Falling Today? ↗
Via Stocktwits
News headline image
2 Stocks Under $50 to Target This Week and 1 We Turn Down
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some... 
Via StockStory
News headline image
Why Did Corcept Therapeutics Stock Surge Over 14% Today? ↗
In the ROSELLA trial, patients receiving relacorilant with nab-paclitaxel saw their risk of death drop by about 35% compared with those given the chemotherapy alone. 
Via Stocktwits
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
1 of Wall Street’s Favorite Stock for Long-Term Investors and 2 Facing Headwinds
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
News headline image
1 Safe-and-Steady Stock to Target This Week and 2 That Underwhelm
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. 
Via StockStory
News headline image
Corcept Insider Transaction Explained After Shares Tumble 50% in One Day ↗
Focused on therapies for endocrine and oncologic conditions, this biotech reported significant insider selling in its latest SEC filing. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
1 Healthcare Stock to Target This Week and 2 We Turn Down
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 17.2% over... 
Via StockStory
Topics Stocks
News headline image
Why Corcept (CORT) Stock Is Trading Lower Today
Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) fell 4.5% in the morning session after the company’s stock faced continued selling pressure following the U.S. Food and Drug... 
Via StockStory
In today's session, these stocks are experiencing unusual volume. ↗
Via Chartmill
Nasdaq, S&P 500 Futures Point To Strong New-Year Open On Wall Street: Why TSLA, BIDU, SLV, STLA Are On Traders' Radar Today ↗
Via Stocktwits
Topics Stocks
News headline image
Stocks making big moves yesterday: FuelCell Energy, Corcept, and PacBio
Check out the companies making headlines yesterday: 
Via StockStory
News headline image
Why Xeris Biopharma Stock Zoomed 7% Higher on Wednesday ↗
One of the company's key drugs won't be challenged by a competing medication anytime soon. 
Via The Motley Fool
News headline image
Why Corcept Therapeutics Plummeted by 50% Today ↗
The final day of 2025 saw the company get a sharp "no" from a top regulator. 
Via The Motley Fool
News headline image
Why Corcept (CORT) Shares Are Falling Today
Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) fell 51.4% in the afternoon session after the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) rejecting... 
Via StockStory
Here are the top movers in Wednesday's session. ↗
Via Chartmill
Top movers analysis in the middle of the day on 2025-12-31: top gainers and losers in today's session. ↗
Via Chartmill
The market is filled with gapping stocks in Wednesday's session. ↗
Via Chartmill
News headline image
3 Cash-Producing Stocks with Questionable Fundamentals
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
News headline image
Why Corcept (CORT) Stock Is Trading Lower Today
Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) fell 4.7% in the afternoon session after investor anxiety mounted ahead of a key U.S. Food and Drug Administration (FDA) decision for its... 
Via StockStory
Topics Artificial Intelligence
News headline image
Corcept (CORT): Buy, Sell, or Hold Post Q3 Earnings?
Corcept has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 13.8% to $81.75 per share while the index has gained 13.9%. 
Via StockStory
Topics Stocks
News headline image
Why Corcept (CORT) Stock Is Down Today
Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) fell 9.2% in the afternoon session after investment bank UBS initiated coverage of the company with a Neutral rating. 
Via StockStory
Topics Artificial Intelligence Economy Supply Chain
News headline image
Corcept (CORT) Q3 2025 Earnings Call Transcript ↗
Corcept (CORT) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
Corcept Therapeutics Inc (NASDAQ:CORT) Presents a Strong Growth and Technical Breakout Case ↗
Corcept Therapeutics (CORT) combines strong fundamentals, including robust revenue growth and a healthy balance sheet, with a positive technical breakout setup. 
Via Chartmill
News headline image
Penumbra, Corcept, Elanco, ResMed, and LeMaitre Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. 
Via StockStory
Topics Economy
News headline image
CORCEPT THERAPEUTICS INC (NASDAQ:CORT): A Case Study in Affordable Growth Investing ↗
Discover Corcept Therapeutics (CORT), a debt-free pharma stock with strong growth forecasts, solid profitability, and a reasonable valuation for balanced investing. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.